Early quantification of HCV core antigen may help to determine the duration of therapy for chronic genotype 2 or 3 HCV infection

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 31, Issue 7, 2012, Pages 1631-1635

  Alsio A ^a   Jannesson, A ^a   Langeland, N ^b,c   Pedersen, C ^d   Farkkila M ^e   Buhl, M R ^f   Morch K ^b,c   Westin, J ^a   Hellstrand, K ^a   Norkrans, G ^a   Lagging, M ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF BERGEN   (Norway)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^e UNIVERSITY OF HELSINKI   (Finland)

^f AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS C ANTIGEN; HEPATITIS C CORE ANTIGEN; PEGINTERFERON ALPHA2A; RIBAVIRIN; UNCLASSIFIED DRUG; ALPHA INTERFERON; ANTIVIRUS AGENT; CORE PROTEIN; MACROGOL DERIVATIVE; NUCLEOCAPSID PROTEIN, HEPATITIS C VIRUS; RECOMBINANT PROTEIN;

ADULT; ANTIGEN DETECTION; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; VIRAL CLEARANCE; BLOOD; CLASSIFICATION; GENETICS; METHODOLOGY; MIDDLE AGED; PROGNOSIS; TIME; VIROLOGY; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; GENOTYPE; HEPACIVIRUS; HEPATITIS C ANTIGENS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROGNOSIS; RECOMBINANT PROTEINS; RIBAVIRIN; TIME FACTORS; TREATMENT OUTCOME; VIRAL CORE PROTEINS; VIRAL LOAD;

EID: 84865579476     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-011-1486-5     Document Type: Article

References (15)

1. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM, PEGASYS International Study Group (2004) Peginterferonalpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 140(5):346-355
2. Dalgard O, Bjøro K, Ring-Larsen H, Bjornsson E, Holberg-Petersen M, Skovlund E, Reichard O, Myrvang B, Sundelöf B, Ritland S, Hellum K, Frydén A, Florholmen J, Verbaan H, North-C Group (2008) Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 47(1):35-42
3. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, Vinelli F, Scotto G, Bacca D, Annese M, Romano M, Zechini F, Sogari F, Spirito F, Andriulli A (2005) Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 352(25):2609-2617
4. Shiffman ML, Pappas S, Nyberg L, Greenbloom S, Gibas A, Bacon B, Rasenack J, Suter F, Diago M, Lin A, Soman A, Zeuzem S (2006) Peginterferon alfa-2a (Pegasys) plus ribavirin (Copegus) for 16 or 24 weeks in patients with HCV genotype 2 or 3. Final results of the ACCELERATE trial. J Hepatol 44(Supp 2):S271
5. Lagging M, Langeland N, Pedersen C, Färkkilä M, Buhl MR, Mørch K, Dhillon AP, Alsiö A, Hellstrand K, Westin J, Norkrans G, NORDynamIC Study Group (2008) Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 47 (6):1837-1845. doi:10.1002/hep.22253
6. Lagging M, Alsiö A, Langeland N, Pedersen C, Färkkilä M, Buhl MR,Mørch K, Hellstrand K, Norkrans G (2011) Early determination of hepatitis C virus RNA may help to decide the duration of therapy for chronic hepatitis C virus genotype 2/3 infection. Hepatology 53 (3):1067-1068. doi:10.1002/hep.23962
7. Lagging M, Alsiö S, Hellstrand K, Norkrans G, NORDynamIC Study Group (2011) Is HCV RNA analysis at day 7 cost-effective in deciding the duration of therapy in chronic HCV genotype 2/3 infection? J Hepatol 54(4):835-836. doi:10.1016/j. jhep.2010.09.038
8. Diago M, Shiffman ML, Bronowicki JP, Zeuzem S, Rodriguez-Torres M, Pappas SC, Tietz A, Nelson DR (2010) Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin. Hepatology 51(6):1897-1903. doi:10.1002/hep.23531
9. Sarrazin C, Shiffman ML, Hadziyannis SJ, Lin A, Colucci G, Ishida H, Zeuzem S (2010) Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy. J Hepatol 52(6):832-838. doi:10.1016/j.jhep.2010.01.030
10. Park Y, Lee JH, Kim BS, Kim do Y, Han KH, Kim HS (2010) New automated hepatitis C virus (HCV) core antigen assay as an alternative to real-time PCR for HCV RNA quantification. J Clin Microbiol 48(6):2253-2256
11. Medici MC, Furlini G, Rodella A, Fuertes A, Monachetti A, Calderaro A, Galli S, Terlenghi L, Olivares M, Bagnarelli P, Costantini A, De Conto F, Sainz M, Galli C, Manca N, Landini MP, Dettori G, Chezzi C (2011) Hepatitis C virus core antigen: Analytical performances, correlation with viremia and potential applications of a quantitative, automated immunoassay. J Clin Virol 51(4):264-269. doi:10.1016/j.jcv.2011.05.003
12. Morota K, Fujinami R, Kinukawa H, Machida T, Ohno K, Saegusa H, Takeda K (2009) A new sensitive and automated chemiluminescent microparticle immunoassay for quantitative determination of hepatitis C virus core antigen. J Virol Methods 157(1):8-14
13. Ross RS, Viazov S, Salloum S, Hilgard P, Gerken G, Roggendorf M (2010) Analytical performance characteristics and clinical utility of a novel assay for total hepatitis C virus core antigen quantification. J Clin Microbiol 48(4):1161-1168
14. Bouvier-Alias M, Patel K, Dahari H, Beaucourt S, Larderie P, Blatt L, Hezode C, Picchio G, Dhumeaux D, Neumann AU, McHutchison JG, Pawlotsky JM (2002) Clinical utility of total HCV core antigen quantification: A new indirect marker of HCV replication. Hepatology 36(1):211-218
15. Chevaliez S, Bouvier-Alias M, Brillet R, Pawlotsky JM (2007) Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method. Hepatology 46(1):22-31